cyclic heptapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide core |
| Molecular weight | 1025.2 g/mol | Calculated for the free base |
| CAS registry number | 189691-06-3 | Free base; the acetate salt has a separate entry |
| Solubility class | Water-soluble | Freely soluble in aqueous media near neutral pH |
| Typical storage | 2 to 8 °C | Protect from light; avoid repeated freeze-thaw cycles |
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
ADP-ribosylation is the addition of one or more ADP-ribose moieties to a protein. It is a reversible post-translational modification that is involved in many cellular processes, including cell signaling, DNA repair, gene regulation and apoptosis. Improper ADP-ribosylation has been implicated in some forms of cancer. It is also the basis for the toxicity of bacterial compounds such as cholera toxin, diphtheria toxin, and others.
== Signs and symptoms == Because of the enormous number of these diseases and the numerous systems negatively impacted, nearly every "presenting complaint" to a healthcare provider may have a congenital metabolic disease as a possible cause, especially in childhood and adolescence. The following are examples of potential manifestations affecting each of the major organ systems.
== Chemistry == Levothyroxine is a synthetic form of thyroxine (T4), which is secreted by the thyroid gland. Levothyroxine and thyroxine are chemically identical: natural thyroxine is also in the "levo" chiral form, the difference is only in terminological preference. T4 is biosynthesized from tyrosine. Approximately 5% of the US population suffers from over- or underproduction of T4 and T3. See Thyroid hormones § Thyroid metabolism for more information on its biosynthesis. Industrially, levothyroxine is made by chemical synthesis. Tyrosine is a common starting material. The produced hormone is incorporated into drugs as its sodium salt, levothyroxine sodium. Solid drugs such as tablets contain the pentahydrate form of the salt. Dextrothyroxine is the mirror form of levothyroxine with the opposite, non-natural chirality.
Sources: en.wikipedia.org
=== Food processing levels === The level of measurement in food processing classification uses nominal or ordinal variables for qualitative grouping of food processing. Processed food classifications, such as the Nova classification, categorise processed foods and often use subjective criteria in processed foods grouping. Nominal food processing classifications group food processing according to qualitative variables, such as raw material sources, purpose of processing, traditional or novel, and type of treatment. Food processing levels (FPL) are derived from ordinal scaling of food processing impact on processed foods. Food processing levels (Table 1) indicate the object and result of food processing and provide means for the use of the extent of food processing at an ordinal scale for various purposes, e.g., processed food classification. The relative impact of FPL on the expected extent of food processing results from the combined effects of physical and chemical changes during food processing as is described in Figure 1.
== History == In the early 1960s, Dr. Arnold Kadish, a physician working at Loma Linda University, developed a closed-loop device for blood glucose control using a double-lumen autoanalyzer to measure blood glucose linked to an intravenous insulin infusion pump. Although it worked, the prototype was considered so bulky, worn as a backpack, and complicated, that it was never commercialized. In 1976, the first commercialized insulin pump was created and was named the Biostator. The pump was a 60 kg bedside device. It also had the capability of monitoring blood glucose levels, so this also doubles as the first continuous glucose monitor. Between 1978 and 1988, Robert Channon, working with Guy's Hospital and the Bristol Royal Infirmary, developed a series of miniature insulin infusion pumps. Today, insulin pumps are so small that they can fit in a pocket or a purse. In the late 1970s and early 1980s, Sandia National Laboratories and the University of New Mexico School of Medicine developed a remotely programmable implantable insulin infusion system that was tested in animals and implanted in human patients beginning in 1981. In 1984, an Infusaid implantable infusion device was used to treat a 22-year-old patient successfully. The insulin pump was first endorsed in the United Kingdom in 2003 by the National Institute for Health and Care Excellence (NICE).
By doing so, individuals with masculinized brains are better able to survive and copulate with as many mates as possible. The masculinization of the brain is mediated both by testosterone levels at the adult stage and by testosterone exposure in the womb. Higher pre-natal testosterone indicated by a low digit ratio as well as adult testosterone levels increased risk of fouls or aggression among male players in a soccer game. Studies have found higher pre-natal testosterone or lower digit ratio to be correlated with higher aggression. The rise in testosterone during competition predicted aggression in males, but not in females. In one experiment, subjects who interacted with handguns showed higher testosterone levels and aggression than those who interacted with toys. One study proposed that natural selection may have caused men to be more sensitive to situations in which their status is challenged, and that testosterone is the key factor that causes these situations to spark into aggression. Structural brain characteristics associated with testosterone levels have also been found to predict individuals' levels of aggression. The Annals of the New York Academy of Sciences has found that the use of anabolic steroids (which increases testosterone) among teenagers is correlated with increased likelihood of using violence. One study found that administering testosterone increased verbal aggression in some participants. A few studies indicate that the testosterone derivative estradiol might play an important role in male aggression.
==== South Korea ==== In 1999 South Korea granted two patents to Pfizer related to sildenafil. The first document guaranteed sole production and sale of the substance until 2012, while the second gave Pfizer the exclusive use to treating erectile dysfunction with sildenafil until 2014. In 2011 Hanmi Pharmaceutical and CJ CheilJedang launched a suit against the exclusive use patent. The Korean Court system made a ruling against Pfizer in June 2012, allowing for the unhindered domestic production of generic prescription sildenafil. In 2012, Viagra lost its position as the top selling erectile dysfunction treatment in South Korea. This development was credited largely "due to the introduction of generic products." Generic sildenafil became publicly available in May. Sales of PalPal by Hanmi Pharmaceuticals totalled ₩22 billion or about 86% the market share of Viagra that year. By 2017, there were over 50 generic sildenafil pills available. During that year Viagra sales slumped to 38% that of Palpal.
Sources: en.wikipedia.org
Vacuum deaerator Composite plastic moulding processes; Production of most types of electric lamps, vacuum tubes, and CRTs where the device is either left evacuated or re-filled with a specific gas or gas mixture; Semiconductor processing, notably ion implantation, dry etch and PVD, ALD, PECVD and CVD deposition and so on in photolithography; Electron microscopy; Medical processes that require suction; Uranium enrichment; Medical applications such as radiotherapy, radiosurgery and radiopharmacy; Analytical instrumentation to analyse gas, liquid, solid, surface and bio materials; Mass spectrometers to create a high vacuum between the ion source and the detector; Vacuum coating on glass, metal and plastics for decoration, for durability and for energy saving, such as low-emissivity glass, hard coating for engine components (as in Formula One), ophthalmic coating, milking machines and other equipment in dairy sheds; Vacuum impregnation of porous products such as wood or electric motor windings; Air conditioning service (removing all contaminants from the system before charging with refrigerant); Trash compactor; Vacuum engineering; Sewage systems (see EN1091:1997 standards); Freeze drying; and Fusion research. In the field of oil regeneration and re-refining, vacuum pumps create a low vacuum for oil dehydration and a high vacuum for oil purification. A vacuum may be used to power, or provide assistance to mechanical devices. In hybrid and diesel engine motor vehicles, a pump fitted on the engine (usually on the camshaft) is used to produce a vacuum.
== Early life and education == Pohl earned her master's degree in at Radcliffe College. She graduated in 1991 having majored in English and American literature. Her graduate dissertation considered the works of Flannery O'Connor and Walker Percy. After completing her master's, Pohl started a doctoral research programme in chemistry at the University of Wisconsin–Madison. She has said that she was inspired by her Harvard chemistry professor, Dudley R. Herschbach. Her doctoral research involved the synthesis of carbohydrate-based ligands under the supervision of Laura L. Kiessling. She joined Stanford University as a National Institutes of Health postdoctoral fellow in the research group of Chaitan Khosla.
The Department of Biochemistry, Cell and Systems Biology, sometimes abbreviated to BCSB, the department is a research-intensive centre of excellence at the University of Liverpool with significant international expertise in cellular proteomics, metabolomics, systems biology, cell signaling, bioinformatics and structural biology (including protein structure prediction and alphafold applications) that is based in refurbished laboratories and research facilities located in the Bioscience and Nuffield buildings of the Knowledge Centre/Quarter North Campus. With a continuous history of research-led discovery and teaching, BCSB contributes significantly to undergraduate and postgraduate teaching and training and is part of the Institute of Systems, Molecular and Integrative Biology, which was created in 2020 and represents a key research-intensive hub within the broader Faculty of Health and Life Sciences, holding > £300 million in its grant funding portfolios as of 2025. The 125th Anniversary of the founding of the department will be celebrated in 2027.
=== Atomic === A mendelevium atom has 101 electrons. They are expected to be arranged in the configuration [Rn]5f137s2 (ground state term symbol 2F7/2), although experimental verification of this electron configuration had not yet been made as of 2006. The fifteen electrons in the 5f and 7s subshells are valence electrons. In forming compounds, three valence electrons may be lost, leaving behind a [Rn]5f12 core: this conforms to the trend set by the other actinides with their [Rn] 5fn electron configurations in the tripositive state. The first ionization potential of mendelevium was measured to be at most (6.58 ± 0.07) eV in 1974, based on the assumption that the 7s electrons would ionise before the 5f ones; this value has not yet been refined further due to the lack to larger samples of mendelevium. The ionic radius of hexacoordinate Md3+ had been preliminarily estimated in 1978 to be around 91.2 pm; 1988 calculations based on the logarithmic trend between distribution coefficients and ionic radius produced a value of 89.6 pm, as well as an enthalpy of hydration of −3654±12 kJ/mol. Md2+ should have an ionic radius of 115 pm and hydration enthalpy −1413 kJ/mol; Md+ should have ionic radius 117 pm.
=== Urinary tract infections === Urinary tract infections (UTIs) are often due to E. coli entering the urethra and colonizing. The host's immune system will release protamines and other antimicrobials to combat the infection, but OmpT easily degrades the cationic protamine peptides, thus enhancing the risk of infection. There is a genetic link between OmpT and other UTI-mediating factors (such as kpsMT, cnf1, prf, and sfa), but the functional link between these proteins is not well defined.
Sources: en.wikipedia.org
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.
They are related but distinct cyclic peptides. Melanotan II is an earlier and less selective melanocortin analog. Bremelanotide was developed later with a narrower receptor profile and a defined clinical application.
The reviewed product is given by subcutaneous injection using a single-use autoinjector. Administration occurs under prescription supervision. The device delivers one fixed amount per use rather than a measured or adjustable quantity.
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.